BHVN Investor Alert: Levi & Korsinsky Investigates Biohaven Ltd. (BHVN) For Potential Securities Fraud
NEW YORK CITY, NY / ACCESS Newswire / September 11, 2026 / Levi & Korsinsky notifies investors that it has commenced an investigation into Biohaven Ltd. ("Biohaven Ltd.") (NYSE:BHVN) concerning potential violations of the federal securities laws.
Biohaven Ltd. shares fell 14.73% on September 10, 2026, following a partial clinical hold issued by the FDA on the Company's BHV-7000/opakalim program, pausing new patient enrollment. The FDA reportedly "determined that there was insufficient information related to a specific metabolite to assess risks" of a "certain metabolites of BHV-7000 observed in rodent testing." This follows the August 26 announcement of a licensing agreement for Biohaven's Kv7 ion channel platform, led by opakalim.
If you suffered a loss on your Biohaven Ltd. securities and would like to explore a potential recovery under the federal securities laws, Learn More About the Investigation or contact Joseph E. Levi, Esq. via email at [email protected] or call (212)363-7500 to speak to our team of experienced shareholder advocates.
WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
[email protected]
Tel: (212)363-7500
Fax: (212)363-7171
SOURCE: Levi & Korsinsky, LLP